Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Advanced Esophagogastric Cancer
NCT02234596Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2014
- Primary completion
- Apr 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in Esophago-Gastric Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2014; status: completed.
02
Drugs
nintedanib
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT02234596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234596.